1-3 of 3
Norbert Hollaender, PhD
Close
Sort by
Journal Articles

Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study

Yesim Aydinok, MD, Zeynep Karakas, MD, Elena Cassinerio, MD, Noppadol Siritanaratkul, MD, Antonis Kattamis, MD, Aurelio Maggio, MD, Norbert Hollaender, PhD, Bruyère Mahuzier, Pharm D, Brian Gadbaw, MD, Ali T. Taher, MD PhD
Journal: Blood
Blood (2016) 128 (22): 852.
https://doi.org/10.1182/blood.V128.22.852.852
Published: 2016
Journal Articles

Impact Of Ruxolitinib On The Natural History Of Patients With Primary Myelofibrosis: A Retrospective Comparison Of The DIPSS and The Comfort-2 Cohorts

Francesco Passamonti, MD, Margherita Maffioli, MD, Francisco Cervantes, MD, PhD, Alessandro M. Vannucchi, MD, PhD, Enrica Morra, MD, Tiziano Barbui, MD, Caramazza Domenica, MD, Elisa Rumi, MD, Gisslinger Heinz, Laurent Knoops, MD, PhD, Barbara Mora, MD, Norbert Hollaender, PhD, Margaret Squier, MD, PhD, Cristiana Pascutto, Claire N Harrison, DM, FRCP, FRCPath, Mario Cazzola, MD
Journal: Blood
Blood (2013) 122 (21): 4066.
https://doi.org/10.1182/blood.V122.21.4066.4066
Published: 2013
Journal Articles

Ruxolitinib Provides Reductions in Splenomegaly Across Subgroups: An Analysis of Spleen Response in the COMFORT-II Study

Claire N. Harrison, DM, FRCP, FRCPath, Jean-Jacques Kiladjian, MD, PhD, Heinz Gisslinger, MD, Dietger Niederwieser, MD, Francesco Passamonti, MD, Roger J. Waltzman, MD, Norbert Hollaender, PhD, Deborah S. Hunter, PhD, Richard S. Levy, MD, Laurent Knoops, MD, PhD, Francisco Cervantes, MD, PhD, Alessandro M. Vannucchi, MD, Tiziano Barbui, MD, Giovanni Barosi, MD
Journal: Blood
Blood (2011) 118 (21): 279.
https://doi.org/10.1182/blood.V118.21.279.279
Published: 2011